

Supplementary Table 1. Baseline clinical characteristics of non-survivors and survivors among solid malignancy patients

Characteristic	Non-survivors	Survivors	p-value
No. of patients	175 (58.8)	123 (41.2)	
Age (yr)	71 (62–77)	68 (61–77)	0.29
Male sex	125 (71.4)	87 (70.7)	0.90
Localized/distant	140/35	96/27	0.68
Breast	11 (6.3)	5 (4.1)	0.40
Lung	22 (12.6)	13 (10.6)	0.60
Digestive tract	107 (61.1)	63 (51.2)	0.09
Prostate/bladder/kidney	14 (8.0)	21 (17.1)	0.02
Others	21 (12.0)	21 (17.1)	0.22
Cancer status			
Diagnosis	23 (13.1)	14 (11.4)	0.45
Remission	87 (49.7)	72 (58.5)	0.33
Stabilization	20 (11.4)	13 (10.6)	0.57
Progression	42 (24.0)	21 (17.1)	0.37
Underlying disease, overlapped			
Hypertension	71 (40.6)	60 (48.8)	0.16
Diabetes mellitus	75 (42.9)	52 (42.3)	0.92
Cardiovascular disease	40 (22.9)	41 (33.3)	0.048
Chronic pulmonary disease	13 (7.4)	6 (4.9)	0.38
Liver disease	36 (20.6)	14 (11.4)	0.04
Chronic kidney disease	30 (17.1)	33 (26.8)	0.06
Treatment history before ICU admission			
Chemotherapy	36 (20.6)	16 (13.0)	0.15
Adjuvant	11 (6.3)	7 (5.7)	0.35
Palliative	22 (12.6)	12 (9.8)	0.21
Radiotherapy	4 (2.3)	5 (4.1)	0.21
Concurrent chemoradiation therapy	12 (6.9)	9 (7.3)	0.49
Steroid	0 (0)	0 (0)	
Admission (day)	7 (3–19)	30 (15–56)	
ICU admission (day)	3 (2–9)	9 (5–21)	<0.001
ICU admission to CRRT start (day)	1 (0–2)	0 (0–1)	0.01
Body mass index (kg/m ²)	22.6 (19.4–25.4)	22.5 (20.8–25.3)	0.37
Mean arterial pressure (mmHg)	74 (66–84)	80 (71–93)	<0.001
Heart rate (beat/min)	109 ± 23	97 ± 25	<0.001
ICU risk factor			
Ventilator use	125 (71.4)	55 (44.7)	<0.001
Vasopressor use	146 (83.4)	66 (53.7)	<0.001
SOFA score	13 (10–15)	9 (6–11)	<0.001
6-Hr urine output before CRRT (mL)	70 (20–185)	136 (29–349)	0.006
Sepsis	80 (45.7)	30 (24.4)	<0.001
Trauma	3 (1.7)	3 (2.4)	0.66
Surgery	44 (25.1)	27 (22.0)	0.52
Cause of ICU admission			
Acute kidney injury	47 (26.9)	70 (56.9)	<0.001
Respiratory failure	39 (22.3)	17 (13.8)	0.07
Shock	89 (50.9)	36 (29.3)	<0.001

(Continued to the next page)

Supplementary Table 1. Continued

Characteristic	Non-survivors	Survivors	p-value
Acute kidney injury etiology			
Sepsis	97 (55.4)	49 (39.8)	0.008
Ischemia/shock	50 (28.6)	34 (27.6)	0.86
Drugs	12 (6.9)	9 (7.3)	0.88
Tumor lysis syndrome	2 (1.1)	0 (0)	
Urinary tract obstruction	1 (0.6)	12 (9.8)	<0.001
Others	12 (6.9)	19 (15.4)	0.02
CRRT indication, overlapped			
Sustained oliguria	118 (67.4)	45 (36.6)	<0.001
Uncontrolled volume overload	87 (49.7)	67 (54.5)	0.42
Intractable hyperkalemia	15 (8.6)	10 (8.1)	0.89
Severe acidosis	70 (40.0)	24 (19.5)	<0.001
Others	61 (34.9)	61 (49.6)	0.01
CRRT duration (hr)	24 (9–65)	48 (28–119)	<0.001
Downtime (hr)	1 (0–3)	2 (1–8)	0.001
CRRT prescription			
Prescribed dose (mL/kg/hr)	38.7 (35.3–41.6)	37.7 (35.4–40.0)	0.27
Delivered CRRT dose (mL/kg/hr)	33.2 (30.4–37.7)	32.9 (29.8–35.9)	0.26
Laboratory finding			
White blood cell ($\times 10^3/\mu\text{L}$)	13.5 (7.6–20.6)	12.1 (8.0–17.1)	0.28
Hemoglobin (g/dL)	10.0 (8.3–11.4)	9.8 (8.8–11.5)	0.59
RDW-CV (%)	15.6 (14.5–17.1)	15.5 (14.1–16.9)	0.63
Platelet ($\times 10^3/\mu\text{L}$)	111 (70–175)	181 (108–240)	<0.001
Total protein (g/dL)	5.1 \pm 0.9	5.9 \pm 1.1	<0.001
Albumin (g/dL)	2.7 (2.4–3.1)	3.1 (2.7–3.6)	<0.001
Potassium (mmol/L)	4.4 (3.9–5.2)	4.3 (3.9–5.3)	0.64
Arterial pH	7.26 (7.14–7.36)	7.34 (7.23–7.39)	<0.001
Bicarbonate (mEq/L)	15.8 \pm 6.5	16.9 \pm 6.7	0.17
BUN (mg/dL)	50 (26–68)	60 (34–91)	0.004
Creatinine (mg/dL)	2.3 (1.5–3.3)	3.1 (1.8–5.0)	<0.001
Uric acid (mg/dL)	7.1 (5.4–9.4)	8.1 (5.6–11.2)	0.04
Corrected calcium (mg/dL) ^a	8.9 (8.4–9.5)	8.8 (8.3–9.3)	0.06
Phosphorus (mg/dL)	5.1 (3.9–6.9)	5.2 (3.6–7.3)	0.97
Lactic acid (mmol/L)	6.2 (3.0–10.9)	2.5 (1.2–4.8)	<0.001
PT INR	1.61 (1.36–2.08)	1.29 (1.18–1.58)	<0.001
BNP (pg/mL)	306 (222–698)	277 (138–778)	0.44
Pro-BNP (pg/mL)	2,640 (647–8,964)	1,668 (662–8,146)	0.56

Data are expressed as number (%), median (interquartile range), or mean \pm standard deviation.

BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CRRT, continuous renal replacement therapy; ICU, intensive care unit; PT INR, prothrombin time international normalized ratio; RDW-CV, red cell distribution width-coefficient of variation; SOFA, Sequential Organ Failure Assessment.

^aCorrected calcium (mg/dL) = measured total Ca (mg/dL) + 0.8 \times [4 – measured serum albumin (g/dL)].